Basic IHC Final

81
Immunohistochemistry Practical issues Dr Santosh Menon Assistant Professor, Pathology Tata Memorial Hosipital

description

TMH proceedings 2010-2011,pdf

Transcript of Basic IHC Final

Page 1: Basic IHC Final

Immunohistochemistry Practical issues

Dr Santosh MenonAssistant Professor, Pathology

Tata Memorial Hosipital

Page 2: Basic IHC Final

What is IHC?

• A method that uses antibodies to identify, locate, and stain specific protein molecules in tissue sections (visualized using a microscope)

• Used to diagnose the type of cancer and to help determine the patient's prognosis or as a predictive marker of therapeutic response.

Page 3: Basic IHC Final

WHY IS IHC IMPORTANT in surgical pathology practice?

• cell lineage and tissue type

• prognostic markers

• Quantification; it is no longer enough that the 'stain' is there; rather it is a question of 'How much is there?'

• Predictive markers for targeted therapy

• Patients are knowledgeable…thanks to internet

Page 4: Basic IHC Final

CD20 and Rituximab

CD20

Page 5: Basic IHC Final

C-erbB2 and Herceptin in breast CA

Page 6: Basic IHC Final

C-kit and imatinib in GIST

Page 7: Basic IHC Final

Immunohistochemistry

• Manual

• Automated

Page 8: Basic IHC Final

Basis of Immunology

Simple Principle

Antigen + Antibody = Complex

Immunohistochemistry is a technique based on the selective binding of specific antibodies to specific antigenic sites on a cell, in a precise

lock and key mechanism

Presenter
Presentation Notes
The basis of IHC is the complex formed by the antigen and specific antibody. This reaction occurs in the body frequently. Using this principle in the labs we have the science of IHC which is a technique based on selective binding of antibody with the antigen in a lock and key type of mechanism.
Page 9: Basic IHC Final

What is an Antigen?Any substance that can trigger the

production of antibodies is called an antigen

What is an Antibody?Antibodies are proteins called

immunoglobulins

Antigen

Antibody

Presenter
Presentation Notes
This brings us to some definitions of what is an antigen and what is an antibody. (Read it out here) and point out the areas in the diagram.
Page 10: Basic IHC Final

Antigen

Primary Antibody

Labeled Secondary Antibody

Cell with antigens on surface

Page 11: Basic IHC Final

Antigen

B

B

PX

PX

PX

B

Avidin Biotin Complex

DAB+H2O2

IHC

Primary Antibody

Labeled Secondary Antibody

Cell with antigens on surface

Detection system

Chromogen

Page 12: Basic IHC Final

Detection system

Primary Antibody

Tissue section with antigen

Page 13: Basic IHC Final

Primary Antibodies

• Polyclonal antibodies: Heterogeneous population of antibodies, produced against several epitopes on a single antigen- multiple clones produce the antibodiesMore tolerant to retrieval techniquesSpecificity is less

• Monoclonal antibodies: Homogenous population of antibodies for a single epitope – from a single clone of B-cellsMore specific Less cross reactivityLess background non specific staining

Page 14: Basic IHC Final

Pure single Ab

After immunization, the mouse spleen contains B cells producing specific antibodies.Each B cell produces only one kind of antibody, which binds to its specific antigen. Conventional antiserum is the mixture of all antibodies produced by B cells from spleen.If a single B cell was picked up and cultured, then it will produce only one kind of antibody. But B cell can not survive well in the culture.Myeloma cell can be cultured in the test tube, but can not produce useful antibody.Each hybridoma line can produce pure single antibody, called monoclonal antibody.If B cell is fused with myeloma, the fused cell might be cultured and produce antibody.

Adapted from Milstein (1980) Scientific American, Oct. p.58

12

34

mmm

m

12 3

4

1 2 3 4

Monoclonalantibodies

Cell fusion

Spleen cells

+Myeloma

x

Antiseum

Antigen

Immunization

A mixture of all Ab

1 23 4

BALB/c

1 2 3 4

1 23 4

B cell

Presenter
Presentation Notes
說明文字
Page 15: Basic IHC Final

Primary Antibody vial

Page 16: Basic IHC Final

How do we start with a new antibody?

Page 17: Basic IHC Final

If you have acquired a new antibody…… Titration is a must

Date Antibody Used

Dilution Appropriate dilution

Remarks

04-04-08 CD20 1:50, 1:1001:200

1:100 GOOD

05-05-08 CD3 1:1001:2001:300

1:200 BEST

Page 18: Basic IHC Final

Positive controls

CYTOKERATIN

CD3

CD20

Page 19: Basic IHC Final

Negative control

Same steps but with omission of primary antibody

Page 20: Basic IHC Final

Validation of new antibodyAntibody_CD138______ Clone M115 CodeNo._M7228

Vendor _ ___ Batch/Lot No._00037097__________

Comments:

Sign: Date:

S.N0 BLOCK MANUFACT.DILn. REMARKSPATHNO. TISSUE 1:50

1 32320BX “ Satisfactory.

2 32210BX “ Satisfactory

3 18083BX “ Satisfactory

4 14597BZ “ Satisfactory

Page 21: Basic IHC Final

Workflow in IHC lab

Page 22: Basic IHC Final

Workflow in IHC: Making an entry

Making the required entries

Page 23: Basic IHC Final

Blocks are cut in routine manner

Page 24: Basic IHC Final

Tissue sections on poly-L-lysine coated slides

Page 25: Basic IHC Final

Bind Primary antibody

Wash

Biotinylated 2nd

antibody

Wash

Chromogen development

Counterstain dehydrate coverslip examine

Block non-sp binding

Deparaffinize

XyleneBlock

endogenous peroxidase

Antigen Retrieval

Page 26: Basic IHC Final

Antigen retrieval -standardization

• Proteolytic enzyme methods• Heat induced epitope retrieval

MicrowavePressure cooker

Achieving the desired temperaturepH of buffer- calibration

Holding times

Page 27: Basic IHC Final

Why is antigen/epitope retrieval necessary? ……..Formalin Fixation

Page 28: Basic IHC Final

Slides immersed in buffer solution

Page 29: Basic IHC Final
Page 30: Basic IHC Final

Scientific pressure cooker

Page 31: Basic IHC Final

Microwave

Page 32: Basic IHC Final

Primary Antibody

Page 33: Basic IHC Final

Primary Antibody vial -1ml

After opening make 20 aliquots of 50 microlitre each

Page 34: Basic IHC Final
Page 35: Basic IHC Final

For daily use make fresh dilutions of primary

antibodies from aliquots

Page 36: Basic IHC Final

Micropippettes

Page 37: Basic IHC Final

Micropippettes

Page 38: Basic IHC Final

Have a daily dilution chart as a spreadsheet

Antibody dilution chart Date 10/06/2010

Antibody Retrieval method Dilution

1 CD20 TE-Pascal 1:100

2 MPO SC-Microwave 1:300

3 CD23 TE-Microwave 1:100

4 ER SC-Pascal 1:50

Page 39: Basic IHC Final

Making the dilutions of antibodies with buffer/diluent

Page 40: Basic IHC Final

Washings and wiping

Page 41: Basic IHC Final

Primary antibody on slide

Page 42: Basic IHC Final
Page 43: Basic IHC Final

Incubation in humidity chambers

Page 44: Basic IHC Final

What are we looking for in IHC?

Coloured visual product demonstrating an antigen antibody reaction:Brown colour (DAB)Red colour (PAP-APAAP)Greenish yellow in

immunoflourescence

Page 45: Basic IHC Final
Page 46: Basic IHC Final

Issues related to interpretation

Page 47: Basic IHC Final

Where should we look for the colour?

• Knowledge of Ag location is a must• Knowledge of pattern of staining is

essential• Cytoplasmic (diffuse,paranuclear,

perinuclear)• Nuclear (diffuse, nucleolar)• Membranous (Continuous, broken)• Interstitial• The cell of interest (larger tumor cell etc)

Page 48: Basic IHC Final

An Example of normal lymph node

CD20 CD3

CD23Bcl2

Page 49: Basic IHC Final

Nuclear positivity

ER Mib-1

p63 PR

Page 50: Basic IHC Final

Cytoplasmic positivity

VimentinDesmin

Page 51: Basic IHC Final

Membrane positivity

CD20 c-kit

Page 52: Basic IHC Final

Golgi zone positivity

CD15 CD15

Page 53: Basic IHC Final

Cell of interest

CD30

LCA

Page 54: Basic IHC Final

RS cells in Hodgkin lymphoma

CD30 LCA

Page 55: Basic IHC Final

Cell of interest

CD20

CD163

Page 56: Basic IHC Final

Cell of interest

C-kit LCA

Page 57: Basic IHC Final

Is everything brown positive?No, beware

Page 58: Basic IHC Final

All that is ‘brown’ is not real

• Background staining

• False positivity including artifacts

Page 59: Basic IHC Final

Problem of false brown stain

• Hydrophobic and electrostatic interactions

• Endogenous peroxidase• Endogenous biotin • Antigen diffusion• Antigen retrieval• Polyclonal antibody• Necrotic tissue

Page 60: Basic IHC Final

Unexpected results….rules rather than exception…awareness is the key

• p63 positivity in B-cell lymphomas• C-kit positivity in nasopharyngeal

carcinomas• Aberrant CD4 in myeloid leukemias• CD138 in myelomas and carcinomas• ……….and the list goes on and on……..

Page 61: Basic IHC Final

Background staining

Polyclonal antibody Necrotic tissue

Page 62: Basic IHC Final

Antigen diffusion

k light chain lambda light chain

Page 63: Basic IHC Final

False positivity• Cross reactivity due to epitope sharing

may result in false positivity• An example is CD79a, a B cell marker

cross reacts with smooth muscle• Error in data entry and

mislabelling(MyoD1 and Mib1)

Page 64: Basic IHC Final

Artifacts in IHC

• Edge and trapping artifacts• Desquamation artifacts• Bubble artifacts• Drying artifacts• Artifacts of poor fixation• Precipitated DAB artifacts• Biotin artifacts

Page 65: Basic IHC Final

Edge and trapping artifacts

Page 66: Basic IHC Final

Crushed tissue artefact

Page 67: Basic IHC Final

Deposits artifact

Page 68: Basic IHC Final

When do you call an IHC as negative?

• Do not call an immunostain negative without checking out the positive controls

• Remember the best control is positive internal control

Page 69: Basic IHC Final

An example of breast cancer

Breast Cancer Negative hormonal markers

Positive ER Positive PR

Page 70: Basic IHC Final

When to call tissue immunodead?

• Vimentin immunostain used to decide the immunoreactivity/preservation of antigenicity of tissue.

• Vimentin is virtually present in all tissues and even smallest of biopsies usually show some vimentin reactivity, if well preserved

Page 71: Basic IHC Final

Quality issues and validation

Page 72: Basic IHC Final

Antibody Clone Vendor Dilution 1 2 3-- 31

ER ID5 DAKO !:100 +6 +6 +6

LCA 2B11 DAKO 1:200 +3 +3 +2

Sign

Month: May2008

Daily positive control chart

Page 73: Basic IHC Final

Daily controls

Page 74: Basic IHC Final

Validation of New Control

Old Block New Block

Tissue Path No. Remark Tissue Path No. Remark

BREAST 6223CD DEPLETED

BREAST 5960CD VALIDATED FOR ER

Antibody_ER____________

Vendor_DAKO___ Clone No.__ID5___ CODE No._M7047_________

Batch No.00000072_________ Dilution Factor__1:100____________

Comments:

Sign: Date:6/5/2008

Page 75: Basic IHC Final

How to overcome practical difficulties of variation in IHC

staining related to human errors?

AUTOMATION

Page 76: Basic IHC Final
Page 77: Basic IHC Final

wwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww

Page 78: Basic IHC Final
Page 79: Basic IHC Final

Acknowledgement• Without a technical hand

who has immense dedication and interest in IHC, it is impossible to achieve required results.

Page 80: Basic IHC Final

Acknowledgements• Dr NA Jambhekar Prof & Head• Dr Sumeet Gujral & Dr Subramanian• Mrs Rekha Thorat Senior technical officer• Mr Mahendra Palkar• Mr Aamir Khan• Mr Pritam• Mr Dinkar• Mr Shinde

Page 81: Basic IHC Final